EGFR and non-small cell lung carcinoma: Spence, T. et al. analyzed the EGFR T790M status of 343 sequential patients with NSCLC using ctDNA collected during anti-EGFR treatment; 24% of the patients had the mutation and these patients were treated with osimertinib, a targeted drug approved in this scenario [31].